Table 2 Cox proportional hazard regression illustrating the risk of cardiovascular mortality during 6.7 years of follow-up of the study population having a high plasma concentration of adiponectin

Age

1.12

1.03–1.21

0.005

1.17

1.06–1.30

0.002

1.10

0.93–1.30

0.26

Hypertension

1.28

0.69–2.39

0.43

1.38

0.68–2.81

0.37

1.05

0.27–4,23

0.94

IHD

1.03

0.56–1.92

0.92

0.72

0.34–1.54

0.40

1.57

0.47–5.22

0.46

BMI

0.99

0.92–1.05

0.69

0.93

0.83–1.03

0.17

1.12

1.00–1.24

0.04

CRP

0.99

0.93–1.05

0.79

0.99

0.94–1.04

0.59

0.90

0.67–1.20

0.48

b-glucose

1.14

0.97–1.35

0.11

0.94

0.80–1.11

0.49

1.12

0.99–1.27

0.07

s-HDL

0.61

0.29–1.28

0.19

1.08

0.39–3.07

0.89

0.55

0.11–2.70

0.47

eGFR < 60 mL/min

0.72

0.34–1.55

0.40

0.66

0.28–1.55

0.34

0.78

0.12–5.19

0.79

Hb < 120 g/L

1.13

0.54–2.34

0.75

0.84

0.28–2.53

0.76

2.41

0.71–8.14

0.16

EF < 40 %

1.74

0.81–3.74

0.16

2.37

0.97–5.77

0.06

0.63

0.12–3.38

0.59

NT-proBNP Q4 (>197 ng/L)

2.54

1.21–5.34

0.01

1.62

0.67–3.89

0.28

6.30

1.36–29.14

0.02

Adiponectin Q4 (>12800 pg/mL)

2.35

1.15–4.82

0.02

1.66

0.38–7.26

0.50

5.28

1.59–17.57

0.007